Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial
Yumin Zhou,Fan Wu,Zhe Shi,Jie Cao,Jia Tian,Weimin Yao,Liping Wei,Fenglei Li,Shan Cai,Yao Shen,Zanfeng Wang,Huilan Zhang,Yanfan Chen,Yingyun Fu,Zhiyi He,Chun Chang,Yongliang Jiang,Shujing Chen,Changli Yang,Shuqing Yu,Heshen Tian,Qijian Cheng,Ziwen Zhao,Yinghua Ying,Yong Zhou,Shengming Liu,Zhishan Deng,Peiyu Huang,Yunzhen Zhang,Xiangwen Luo,Haiyan Zhao,Jianping Gui,Weiguang Lai,Guoping Hu,Cong Liu,Ling Su,Zhiguang Liu,Jianhui Huang,Dongxing Zhao,Nanshan Zhong,Pixin Ran,,Zhuxiang Zhao,Sha Liu,Zihui Wang,Longhui Tang,Jinzhen Zheng,Hailin Zhou,Yuliang Cai,Yu Zhang,Haiqing Li,Ping Chen,Fen Jiang,Suizheng Cai,Jian Zhou,Hong Xia,Meijia Wang,Jiaojiao Chu,Xueding Cai,Yazhen Li,Yanfei Bin,Lingshan Zeng,Haiqin Zhang,Hua He,Yichen He,Wenxia Zhou,Li Chen
DOI: https://doi.org/10.1038/s41467-024-51079-1
IF: 16.6
2024-09-30
Nature Communications
Abstract:Abstract Evidence for the treatment of patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) is limited. The efficacy of N-acetylcysteine (an antioxidant and mucolytic agent) for patients with mild-to-moderate COPD is uncertain. In this multicentre, randomised, double-blind, placebo-controlled trial, we randomly assigned 968 patients with mild-to-moderate COPD to treatment with N-acetylcysteine (600 mg, twice daily) or matched placebo for two years. Eligible participants were 40-80 years of age and had mild-to-moderate COPD (forced expiratory volume in 1 second [FEV 1 ] to forced vital capacity ratio <0.70 and an FEV 1 ≥ 50% predicted value after bronchodilator use). The coprimary outcomes were the annual rate of total exacerbations and the between-group difference in the change from baseline to 24 months in FEV 1 before bronchodilator use. COPD exacerbation was defined as the appearance or worsening of at least two major symptoms (cough, expectoration, purulent sputum, wheezing, or dyspnoea) persisting for at least 48 hours. Assessment of exacerbations was conducted every three months, and lung function was performed annually after enrolment. The difference between the N-acetylcysteine group and the placebo group in the annual rate of total exacerbation were not significant (0.65 vs. 0.72 per patient-year; relative risk [RR], 0.90; 95% confidence interval [CI], 0.80–1.02; P = 0.10). There was no significant difference in FEV 1 before bronchodilator use at 24 months. Long-term treatment with high-dose N-acetylcysteine neither significantly reduced the annual rate of total exacerbations nor improved lung function in patients with mild-to-moderate COPD. Chinese Clinical Trial Registration: ChiCTR-IIR-17012604.
multidisciplinary sciences